system
A chat on subreddit /r/wallstreetbets
human
I agree with you as t1d. My intuition is saying very low market for this drug. When trying to improve ha1c's, there's a multitude of steps to take which don't carry the side-effects of these inhibitors. They seem like a last resort for individuals with highly sensitive blood glucose responses. CGM tech has greater a1c reductions, but without these risks.

gpt
SLGT2s are gangbusters for heart failure.  Clinical trial data demonstrates mortality benefit.  
  
 As DM drugs, I almost never prescribe them. Triple oral therapy has only received ADA backing and usually by that time, they need insulin.